Arcadia Investment Management Corp MI reduced its position in shares of Pfizer, Inc. (NYSE:PFE) by 6.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 52,958 shares of the biopharmaceutical company’s stock after selling 3,642 shares during the period. Arcadia Investment Management Corp MI’s holdings in Pfizer were worth $1,779,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the stock. Shine Investment Advisory Services Inc. acquired a new position in shares of Pfizer in the 2nd quarter valued at $102,000. D. Scott Neal Inc. boosted its position in shares of Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 504 shares during the period. Franklin Parlapiano Turner & Welch LLC acquired a new position in shares of Pfizer in the 1st quarter valued at $121,000. Cascade Investment Advisors Inc. boosted its position in shares of Pfizer by 89.1% in the 2nd quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 2,200 shares during the period. Finally, Perennial Advisors LLC boosted its position in shares of Pfizer by 7.9% in the 2nd quarter. Perennial Advisors LLC now owns 5,132 shares of the biopharmaceutical company’s stock valued at $172,000 after purchasing an additional 376 shares during the period. 69.36% of the stock is currently owned by hedge funds and other institutional investors.
In related news, CEO Ian C. Read sold 197,168 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $6,703,712.00. Following the transaction, the chief executive officer now directly owns 580,318 shares of the company’s stock, valued at approximately $19,730,812. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Frank A. Damelio sold 94,409 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $3,209,906.00. Following the completion of the transaction, the executive vice president now directly owns 337,389 shares in the company, valued at $11,471,226. The disclosure for this sale can be found here. Insiders sold a total of 374,621 shares of company stock worth $12,796,098 over the last three months. 0.06% of the stock is owned by company insiders.
Shares of Pfizer, Inc. (NYSE:PFE) opened at $35.37 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer, Inc. has a 1-year low of $30.51 and a 1-year high of $36.78. The stock has a market capitalization of $211,960.00, a PE ratio of 14.15, a PEG ratio of 2.50 and a beta of 1.01.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. During the same period last year, the business earned $0.61 EPS. The firm’s revenue was up .9% compared to the same quarter last year. sell-side analysts anticipate that Pfizer, Inc. will post 2.6 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.62%. The ex-dividend date is Thursday, November 9th. Pfizer’s payout ratio is 78.53%.
A number of research firms recently weighed in on PFE. ValuEngine upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. J P Morgan Chase & Co set a $39.00 price target on Pfizer and gave the company a “buy” rating in a research report on Wednesday, November 1st. Jefferies Group LLC set a $39.00 price target on Pfizer and gave the company a “neutral” rating in a research report on Thursday. Berenberg Bank set a $36.00 price target on Pfizer and gave the company a “neutral” rating in a research report on Tuesday, October 31st. Finally, Morgan Stanley upgraded Pfizer from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $35.00 to $39.00 in a research report on Wednesday, September 20th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $38.48.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.